Pacific Capital Partners’s AbbVie ABBV Stock Holding History

Pacific Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,522	Closed	-$1.87M	–	39
2024 Q4	$1.87M	Hold	10,522	–	–	1.1%	26
2024 Q3	$2.08M	Hold	10,522	–	–	1.22%	23
2024 Q2	$1.8M	Buy	10,522 +1,496	+17%	+$248K	1.19%	25
2024 Q1	$1.64M	Buy	9,026 +727	+9%	+$125K	1.08%	28
2023 Q4	$1.29M	Buy	8,299 +150	+2%	+$21.9K	0.97%	33
2023 Q3	$1.21M	Buy	+8,149	New	+$1.2M	0.73%	35

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Pacific Capital Partners's ABBV Position: Q1 2025 in Review

Pacific Capital Partners sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 10,522 shares — an estimated $1.87M sold.

Pacific Capital Partners first reported a position in ABBV in Q3 2023 and held it in 6 quarters. The position peaked at $2.08M in Q3 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

Pacific Capital Partners reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
Pacific Capital Partners sold 10,522 AbbVie shares in Q1 2025, an estimated $1.87M.
Pacific Capital Partners first reported a position in AbbVie in Q3 2023 and held it in 6 quarters.
Pacific Capital Partners's AbbVie position peaked at $2.08M in Q3 2024.
3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Pacific Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.